scholarly journals Multiple Myeloma: A Review of Imaging Features and Radiological Techniques

2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
C. F. Healy ◽  
J. G. Murray ◽  
S. J. Eustace ◽  
J. Madewell ◽  
P. J. O'Gorman ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Multiple Myeloma ◽  
Plasma Cells ◽  
Imaging Techniques ◽  
Staging System ◽  
Whole Body ◽  
Emission Computed Tomography ◽  
Whole Body Imaging ◽  
Imaging Features ◽  
Positron Emission

The recently updated Durie/Salmon PLUS staging system published in 2006 highlights the many advances that have been made in the imaging of multiple myeloma, a common malignancy of plasma cells. In this article, we shall focus primarily on the more sensitive and specific whole-body imaging techniques, including whole-body computed tomography, whole-body magnetic resonance imaging, and positron emission computed tomography. We shall also discuss new and emerging imaging techniques and future developments in the radiological assessment of multiple myeloma.

scholarly journals Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab

2020 ◽  
Vol 4 (20) ◽  
pp. 5194-5202
Author(s):  
Amrita Krishnan ◽  
Vikram Adhikarla ◽  
Erasmus K. Poku ◽  
Joycelynne Palmer ◽  
Ammar Chaudhry ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Sensitivity And Specificity ◽  
Imaging Techniques ◽  
Phase 1 ◽  
Whole Body ◽  
Human Antibody ◽  
Whole Body Imaging ◽  
Positron Emission ◽  
Pet Ct

Abstract 18F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is one of the most widely used imaging techniques to detect multiple myeloma (MM). Intracellular FDG uptake depicts in vivo metabolic activity, which can be seen in both malignant and nonmalignant cells, resulting in limited sensitivity and specificity. Our group showed preclinically that tracing MM dissemination using a CD38-directed human antibody, daratumumab, that is radioconjugated with 64Cu via the chelator DOTA (64Cu-daratumumab), led to improved sensitivity and specificity over that of FDG. Here, we report the results of a phase 1 trial designed to (1) assess the safety and feasibility of 64Cu-daratumumab PET/CT and (2) preliminarily evaluate and characterize the ability of 64Cu-daratumumab to accurately detect or exclude MM lesions. A total of 12 daratumumab-naive patients were imaged. Prior to the injection of 15 mCi/5 mg of 64Cu-daratumumab, patients were treated with 0 (n = 3), 10 (n = 3), 45 (n = 3), or 95 mg (n = 3) of unlabeled daratumumab to assess its effect on image quality. No significant adverse events were observed from either unlabeled daratumumab or 64Cu-daratumumab. Of the dose levels tested, 45 mg unlabeled daratumumab was the most optimal in terms of removing background signal without saturating target sites. 64Cu-daratumumab PET/CT provided safe whole-body imaging of MM. A trial comparing the sensitivity and specificity of 64Cu-daratumumab PET/CT with that of FDG PET/CT is planned. This trial was registered at www.clinicaltrials.gov as #NCT03311828.

scholarly journals Imaging of Multiple Myeloma

2019 ◽  
Vol 191 (09) ◽  
pp. 805-816
Author(s):  
Aleksander Kosmala ◽  
Thorsten Bley ◽  
Bernhard Petritsch
Keyword(s):  
Computed Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Imaging Techniques ◽  
Therapy Monitoring ◽  
Whole Body ◽  
Emission Computed Tomography ◽  
Cross Sectional ◽  
Therapeutic Implications

Background Multiple myeloma is a malignant hematological disease characterized by uncontrolled proliferation of monoclonal plasma cells mainly in the bone marrow. Imaging plays a crucial role in diagnosis and follow-up. Method This literature review provides information about multiple myeloma, its precursor diseases, and available imaging techniques. Advantages and limitations as well as possible prognostic and therapeutic implications of the different imaging methods are presented in the context of the current literature. Results and Conclusion Cross-sectional imaging has replaced conventional X-ray skeletal survey. Widely available whole-body computed tomography is routinely used to detect osteolytic lesions. Magnetic resonance imaging is the most sensitive technique to identify bone marrow infiltration and is recommended in multiple myeloma precursor diseases. Positron emission computed tomography combines morphological and functional imaging. It is mainly used for follow-up, therapy monitoring, and response evaluation. Key points:  Citation Format

scholarly journals Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma

Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 134 ◽  
Author(s):  
Christos Sachpekidis ◽  
Hartmut Goldschmidt ◽  
Antonia Dimitrakopoulou-Strauss
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Multiple Myeloma ◽  
Bone Marrow ◽  
Bone Disease ◽  
Emission Tomography ◽  
Whole Body ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg

Multiple myeloma (MM) is a plasma cell disorder, characterized by clonal proliferation of malignant plasma cells in the bone marrow. Bone disease is the most frequent feature and an end-organ defining indicator of MM. In this context, imaging plays a pivotal role in the management of the malignancy. For several decades whole-body X-ray survey (WBXR) has been applied for the diagnosis and staging of bone disease in MM. However, the serious drawbacks of WBXR have led to its gradual replacement from novel imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT). PET/CT, with the tracer 18F-fluorodeoxyglucose (18F-FDG), is now considered a powerful diagnostic tool for the detection of medullary and extramedullary disease at the time of diagnosis, a reliable predictor of survival as well as the most robust modality for treatment response evaluation in MM. On the other hand, 18F-FDG carries its own limitations as a radiopharmaceutical, including a rather poor sensitivity for the detection of diffuse bone marrow infiltration, a relatively low specificity, and the lack of widely applied, established criteria for image interpretation. This has led to the development of several alternative PET tracers, some of which with promising results regarding MM detection. The aim of this review article is to outline the major applications of PET/CT with different radiopharmaceuticals in the clinical practice of MM.

scholarly journals Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease

2014 ◽  
Vol 20 (23) ◽  
pp. 5888-5897 ◽  
Author(s):  
Matthew J. Pianko ◽  
Evangelos Terpos ◽  
G. David Roodman ◽  
Chaitanya R. Divgi ◽  
Sonja Zweegman ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Multiple Myeloma ◽  
Bone Disease ◽  
Low Dose ◽  
Imaging Techniques ◽  
Whole Body ◽  
Advanced Imaging ◽  
Myeloma Bone Disease ◽  
Low Dose Computed Tomography

scholarly journals Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review

2013 ◽  
Vol 47 (3) ◽  
pp. 206-218 ◽  
Author(s):  
Mario Ciliberto ◽  
Fabio Maggi ◽  
Giorgio Treglia ◽  
Federico Padovano ◽  
Lucio Calandriello ◽  
...  
Keyword(s):  
Systematic Review ◽  
Fdg Pet ◽  
Imaging Techniques ◽  
Diagnostic Methods ◽  
Whole Body ◽  
Published Data ◽  
Whole Body Imaging ◽  
Positron Emission ◽  
Pet Ct ◽  
Fluorine 18 Fluorodeoxyglucose

Abstract Background. The aim of the article is to systematically review published data about the comparison between positron emission tomography (PET) or PET/computed tomography (PET/CT) using Fluorine-18-Fluorodeoxyglucose (FDG) and whole-body magnetic resonance imaging (WB-MRI) in patients with different tumours. Methods. A comprehensive literature search of studies published in PubMed/MEDLINE, Scopus and Embase databases through April 2012 and regarding the comparison between FDG-PET or PET/CT and WB-MRI in patients with various tumours was carried out. Results. Forty-four articles comprising 2287 patients were retrieved in full-text version, included and discussed in this systematic review. Several articles evaluated mixed tumours with both diagnostic methods. Concerning the specific tumour types, more evidence exists for lymphomas, bone tumours, head and neck tumours and lung tumours, whereas there is less evidence for other tumour types. Conclusions. Overall, based on the literature findings, WB-MRI seems to be a valid alternative method compared to PET/CT in oncology. Further larger prospective studies and in particular cost-effectiveness analysis comparing these two whole-body imaging techniques are needed to better assess the role of WB-MRI compared to FDG-PET or PET/ CT in specific tumour types.

THE MATHEMATICS OF THE IMAGING TECHNIQUES OF MEG, CT, PET AND SPECT

2006 ◽  
Vol 16 (06) ◽  
pp. 1671-1687 ◽  
Author(s):  
A. S. FOKAS ◽  
V. MARINAKIS
Keyword(s):  
Computed Tomography ◽  
Single Photon ◽  
Imaging Techniques ◽  
Photon Emission ◽  
Real Data ◽  
Emission Computed Tomography ◽  
Single Photon Emission ◽  
Positron Emission ◽  
Single Photon Emission Computed ◽  
Photon Emission Computed Tomography

The imaging techniques of magnetoencephalography (MEG), computed tomography (CT), positron emission tomography (PET) and single photon emission computed tomography (SPECT) are reviewed, and the analytical solutions of the relevant inverse problems are presented. The numerical implementation of the exact formulas yield accurate reconstructions for both realistic phantoms as well as real data.

scholarly journals Imaging Diagnosis of a Shoulder Tumor – Case Presentation

2018 ◽  
Vol 1 (Supplement) ◽  
pp. 39
Author(s):  
R. Turcu ◽  
A. Barbilian
Keyword(s):  
Magnetic Resonance Imaging ◽  
Computed Tomography ◽  
Magnetic Resonance ◽  
Imaging Techniques ◽  
Emission Computed Tomography ◽  
Resonance Imaging ◽  
Slow Increase ◽  
Tumor Pathology ◽  
Positron Emission ◽  
Patient Will

Abstract Introduction. The most common and used molecular imaging techniques used in tumor pathology are the following: optics such as fluoroscopy, bioluminescence, and spectroscopy, radionuclides such as positron emission computed tomography, magnetic resonance with or without contrast substance, ultrasound and computed tomography. Material and method. A 39-year-old male patient accused having a shoulder tumor beginning 6 months before with a slow increase in volume without symptoms, pain, local temperature changes, and neurological phenomena. The clinical examination revealed the presence of an elastic consistency tumor, adherent to the bone but movable in soft adjacent tissues, without spontaneous and palpation pain, and local swelling. There was a slight functional embarrassment in conducting the abduction maneuver, but without limiting the amplitude of the movement. Results. Radiography of the shoulder did not reveal any significant changes. Magnetic resonance imaging of the shoulder and contrast-enhanced magnetic resonance imaging of the shoulder were performed. The evoked changes required a computed tomography of the shoulder. Conclusion. The thorough analysis of the imaging investigations and the clinical, paraclinical, and biological context of the patient will lead to the indication of the treatment and the optimal surgical time.

Sign in / Sign up

Export Citation Format

Share Document